No full federal rescheduling of psilocybin passes this year; FDA and DEA tracks stay separate.

Even though some states have loosened their rules around psilocybin (the active ingredient in 'magic mushrooms'), the federal government won't change its nationwide rules this year. The FDA (the US drug regulator) and the DEA (the federal drug enforcement agency) each have their own separate, slow-moving processes — and neither is ready to act. This means psilocybin remains a Schedule I drug federally, the same legal category as heroin.

Congress won't get ahead of voters; scheduling reform requires FDA approval first, then a slow DEA process. My district isn't there yet.